AN OPEN-LABEL, MULTICENTER, PHASE I STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY CLINICAL ACTIVITY OF RO7428731 IN PARTICIPANTS WITH GLIOBLASTOMA EXPRESSING MUTANT EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III

Registry ID

BP42573

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

HOFFMANN-LA ROCHE LIMITED

Start date

2023-06-22

Last update

2021-10-20

Conditions

• GLIOBLASTOMA

Related clinical trials

• A PHASE 1/2 STUDY TO ASSESS BDTX-1535, AN ORAL EGFR INHIBITOR, IN PATIENTS WITH GLIOBLASTOMA OR NON-SMALL CELL LUNG CANCER
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF OPTUNE® (TTFIELDS, 200 KHZ) CONCOMITANT WITH MAINTENANCE TEMOZOLOMIDE AND PEMBROLIZUMAB VERSUS OPTUNE® CONCOMITANT WITH MAINTENANCE TEMOZOLOMIDE AND PLACEBO FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA
• A PHASE 3, OPEN-LABEL, RANDOMIZED 2-ARM STUDY COMPARING THE CLINICAL EFFICACY AND SAFETY OF NIRAPARIB WITH TEMOZOLOMIDE IN ADULT PARTICIPANTS WITH NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA
• A RANDOMIZED PHASE II STUDY ON INTRA-ARTERIAL CARBOPLATIN COMBINED WITH CAELYX COMPARED TO INTRA-ARTERIAL CARBOPLATIN COMBINED WITH ETOPOSIDE PHOSPHATE FOR PROGRESSING GLIOBLASTOMA AT FIRST OR SECOND RELAPSE.
• BIOMARKER AND TUMOR CELL CULTURE-DRIVEN PILOT TRIAL FOR TREATMENT OF RECURRENT GLIOBLASTOMA
• A RANDOMIZED CONTROLLED TRIAL OF TAMOXIFEN VERSUS ETOPOSIDE FOR PATIENTS WITH FIRST RECURRENCE OF GLIOBLASTOMA MULTIFORME

View on source registry